Exploring New Frontiers: FcRn Inhibitors to Broaden Therapeutic Impact
Autoimmune disease management has undergone revolutionary change with the introduction of Argenx's VYVGART, the trailblazing FcRn inhibitor that marked the beginning of a new therapeutic era. This groundbreaking medication has achieved outstanding clinical results in generalized myasthenia gravis (gMG) treatment and continues progressing through clinical development for immune...